López-Arroyo JL, Rico-Ramos HJ, Portillo-García ML

Language: Spanish
References: 11
Page: 262-265
PDF size: 265.48 Kb.

ABSTRACT

Background: Chronic myeloid leukemia is a myeloproliferative disorder which results from the translocation t(9;22)(q34;q11). Imatinib mesylate is an inhibitor of kinase tyrosine that has proved to be useful in patients with chronic myeloid leukemia. Our aim was to evaluate the major molecular response to 12 months with triple therapy, analyze the evolution of these patients, and the hematological and non-hematological toxicity.
Methods: It was performed a longitudinal study in patients with diagnosis of chronic myeloid leukemia who were treated with sequential triple therapy: Pegylated interferon alpha 2a (90 µg/week for four weeks) + imatinib (800 mg a day for 30 days) + cytarabine (20 mg/m² from day 1 to 10). Molecular and hematologic responses at 12 months of treatment were analyzed.
Results: Thirty eight patients with chronic myeloid leukemia were eligible; the mean age was 43.4 years and the medians of hemoglobin levels, leukocyte and platelet counts at diagnosis were 10 g/dL (5.1 to 16.0 g/dL), 208 000/µL³ (10 600 to 529 000/µL³) and 573 500/µL³ (130 000 to 4 272 000/µL³), respectively. According to the Sokal score, 68.4 % had low risk, 26.3 % intermediate and 5.3 % high risk.
Conclusions: The hematologic response was similar to that reported in the IRIS study, but the molecular response was greater in more cases. The adverse hematological effects grades 3-4 and non-hematological were signifi cative: 45 % and 87 %, which forces to continous monitoring. The combination of interferon alpha 2a, cytarabine and a high-dose of imatinib induced the major molecular response, of 68.4 %, at 12 months.

REFERENCES

1. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: Biology and therapy. Ann Intern Med. 1999;131:207-19.

2. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STE- 571 inhibition of Abelson tyrosin kinase. Science. 2000;(5486):1938-42.

3. Góngora-Biachi RA, Selva-Pallares JE, Gómez-Almaguer D, Meillón-García L, Vela-Ojeda J, Espinosa- Larrañaga F. Declaración mexicana de posición para el tratamiento de la leucemia mieloide crónica. Rev Hematol. 2005;6(Supl 2):S1-14.

4. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.

5. Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party. Blood. 2009;113 (15):3429-34.

6. Preudhomme C, Guilhot J, Nicolini FE, Guerci- Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511-21.

7. Hughes TP, Kaeda J, Brandford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(9): 1423-32.

8. Thiesing JT, Ohno J, Kolibaba KS, Druker BJ. Effi cacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against BCR-ABL-positive cells. Blood. 2000;96 (9);3195-9.

9. Baccaranni M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, et al. Imatinib and pegylated human recombinant interferon-alpha 2b in early chronic- phase chronic myeloid leukemia. Blood. 2004;104 (13):4245-51.

10. Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, et al. Results of a prospective phase 2 study combing imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood. 2003;102(13):4298-305.

11. Hughes TP, Hochhaus A, Brandford S, Müller MC, Kaeda JS, Foroni L, et al. Long-term prognosis signifi cance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;11(19): 3758-65.